Why Choose Australia for Clinical Trials?

Australia, renowned for its vast landscapes and unique wildlife, is not only a beautiful country but also a thriving hub for clinical trials. With a population of approximately 27 million, Australia offers a unique advantage in terms of size, diversity and infrastructure — these factors converge to create an environment conducive to exceptional clinical trial outcomes, or what we like to call the “Australian Advantage.” 

World-Class Infrastructure

Australia’s healthcare system and well-regulated data management practices create an environment conducive to early clinical trial development. The country’s world-leading medical research infrastructure further enhances the capabilities for conducting innovative trials.

Ethnically-Diverse Participants

Australia is considered to be one of the world’s major ‘immigrant nations’ with well over a quarter of the population being born overseas, and half of the population being born overseas or having at least one parent born overseas. For this reason, Australia’s diversity becomes a significant strength in clinical trial success. This diversity allows for a broad range of participant demographics, contributing to robust research outcomes.

Globally Recognised Research

Australia’s commitment to biotech innovation and medical research has earned it a place in the Top 5 globally. Studies conducted in Australia are widely accepted by international regulatory authorities, including the FDA and EMA, highlighting the nation’s reputation for excellence in research.

Data Exclusivity

Australia’s secure intellectual property system, including patent protection and five years of data exclusivity for new pharmaceutical products, provides added protection for innovators and investors.

Commercial Benefits

Running early-phase clinical trials in Australia is significantly more cost-effective than in many parts of Europe or the United States. Moreover, Australia’s generous R&D tax incentives offer additional commercial advantages, making it an attractive destination for research and development.

Accelerated Timelines

Australia boasts a streamlined regulatory and ethics review process, leading to faster completion of clinical trials. Notably, Phase I trials in Australia do not require an Investigational New Drug (IND) application, and the Clinical Trial Notification (CTN) scheme sets a global benchmark for reducing the regulatory burden on clinical trial sponsors.

For all of these reasons and more, Australia attracts sponsors from around the world who have a fervent desire to capitalise on the country’s population diversity, strategic location, world-class research and development facilities, healthcare system, as well as very attractive tax rebates provided by the Federal Government.

Accelagen: Locally Positioned, Globally Adept

As the world looks toward Australia for clinical research excellence, Australian-based CRO Accelagen stands ready to lead the way in accelerating the future of human health and wellness on a global scale.

Headquartered in this thriving clinical trials market, Accelagen is strategically positioned in the heart of the fastest-growing clinical trials market, combining local positioning with global expertise. 

Bringing over a decade of success, Accelagen’s experience spans a wide spectrum of health, wellness, and disease areas, offering comprehensive services from Regulatory Affairs, to Clinical Trials, Biometrics, Medical & Pharmacovigilance, and Strategic Consultation services.

With experience sponsoring regulatory submissions with partners from every region, including Asia-Pacific, North America and Europe, we’d love to talk more about being your local sponsor in the growing Australian market.

Learn more about the ‘Australian Advantage’ and get in touch today → [email protected]